INTRODUCTION

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children and adolescents, with a prevalence of 4%–12% [1]. Approximately 35%–65% of children diagnosed with ADHD show the main symptoms of ADHD and have comorbid disorders as adults [2,3]. There is a 70% chance that a child with ADHD has one or more comorbidities [4]. Psychosocial, cognitive behavioral therapy, and drug therapy may be used to treat ADHD. Among the different treatment options, drug treatment using stimulants is the most effective. A multimodal treatment study of children with ADHD (Multimodal Treatment Study of Children With ADHD study) conducted on 579 children over 14 weeks reported that drug treatment should be prioritized even when behavioral treatment is simultaneous provided [5]. Moreover, considering its efficacy and safety, stimulants such as amphetamine or methylphenidate are more effective than non-stimulants and α2-agonists [6,7].

Amphetamine was first used in the US in the 1930s [8], followed by the use of methylphenidate for the treatment of ADHD. Methylphenidate accounted for approximately 80% of stimulants used for the treatment of ADHD in the US from the late 1980s to the mid-1990s [9]. Dextro- and levo-amphetamine mixtures (product name: Adderall) were also introduced at the same time and are currently used more frequently in the US than methylphenidate. However, in many other countries, methylphenidate remains the main stimulant used for the treatment of ADHD. In the early days, the stimulants used for the treatment of ADHD were short-acting medications. In contrast, recently, long-term drug formulations are used mainly [10]. Stimulants are among the most commonly used medications in children and adolescents, close observations and studies are necessary to assess the effects of stimulants on various movement disorders, including tic disorders and Parkinson’s disease.
ment disorders associated with stimulants include tics that are commonly associated with ADHD, tremors, stereotypies, gait disturbances, chorea, dystonia, akathisia, and Parkinson’s disease (PD). Abnormal movement signs/symptoms in patients with ADHD undergoing stimulant treatment are mostly caused by overuse, abuse, and withdrawal of drugs; however, the symptoms may also develop with drug use in the clinical therapeutic dosage range and may be aggravated by abnormal movement symptoms that the patient previously had [12].

Herein, we review movement disorders caused by stimulant use in ADHD with a focus on studies involving human subjects. We have divided movement disorders into three categories: tic disorders, stereotypies and other movement disorders, and PD.

**TIC DISORDERS**

Tics are sudden, rapid, and repetitive arrhythmic movements or sounds that can develop in any part of the body. Tourette’s disorder is diagnosed when multiple motor and vocal tics last for more than one year, and typically develops at the age of three–eight years. Symptoms peak between the ages of 10 and 12 years and are gradually alleviated throughout puberty. In adulthood, 60%–80% of tic symptoms disappear or decrease significantly [13,14]. ADHD is the most common disease associated with Tourette’s disorder. Approximately 50% of patients with Tourette’s disorder also have ADHD [15], and 8%–10% of children with ADHD develop Tourette’s disorder [16,17]. In certain cases, ADHD and tic disorders develop simultaneously; however, in general, ADHD symptoms appear 2–3 years before tic symptoms develop [18]. Although the causal relationship between ADHD and tic disorders has not been clearly established, the two are neurobiologically related, and there is controversy over the most effective drug for treatment when ADHD and tic disorders co-exist.

In the 1970s and 1980s, several case reports showed that stimulants used for the treatment of ADHD in children led to the development or aggravation of tic disorders [19,20]. Accordingly, the US Food and Drug Administration (FDA) banned the use of stimulants in patients with tic disorders or a family history of tic disorders [21]. In fact, many clinicians have observed that tic disorders develop or worsen after the use of stimulants and patients experience difficulties in responding to treatment outcomes. On the other hand, many important pieces of evidence suggest that stimulants do not affect tic disorders, as shown in Table 1 [22-25]. In a placebo-controlled, double-blind, crossover study, Castellanos et al. [22] administered methylphenidate, d-amphetamine, and placebo to ADHD patients with Tourette’s disorder for nine weeks. In that study, the two stimulants reduced the symptoms of ADHD at all doses. Methylphenidate and d-amphetamine increased the severity of tics, as evaluated using the Yale Global Tic Severity Scale (YGTSS), at medium and high doses in the first cohort. However, in the second and third cohorts tested by the same group, there was no difference in the severity of tics between those who received either of the two stimulants and placebo. Altogether, tic disorder was transiently aggravated in a small number of participants and resolved over time, whereas ADHD symptoms were consistently controlled. Gadow et al. [23] administered three different doses of immediate-release methylphenidate (MPH-IR) for a short period to 71 children with ADHD and Tourette’s disorder (or chronic motor tic disorder), and followed up with the participants from 1989 to 2004. All doses of MPH-IR effectively reduced the severity of ADHD, oppositional defiant disorder, and peer aggression behaviors, and did not aggravate tics compared to placebo. Contrastingly, the teacher ratings showed that MPH-IR improved the frequency and severity of tics. In another multicenter, randomized, double-blind clinical trial published by the Tourette’s Syndrome Study Group in 2002 [24], patients with ADHD and Tourette’s disorder were divided into clonidine only, methylphenidate only, clonidine+methylphenidate,

| Authors                  | Years | No. of participants | Age range (yr) | Study duration | Drug                        | Control                  | Results                        |
|--------------------------|-------|---------------------|----------------|----------------|-----------------------------|--------------------------|--------------------------------|
| Castellanos et al. [22]  | 1997  | 20                  | 9.4 (mean age) | 9 weeks        | MPH 15, 25, 45 mg bid AMP 7.5, 15, 22.5 mg bid | Placebo                  | ADHD symptoms improved without aggravation of tics |
| Nolan et al. [25]        | 1999  | 19                  | 12.3 (mean age) | 6 weeks        | MPH 0.57 mg/kg (mean total daily dose) AMP 5, 10 mg bid MPH+Clonidine | Placebo                  | ADHD symptoms improved without aggravation of tics |
| Tourette’s Syndrome Study Group [24] | 2002 | 136                | 7–14          | 16 weeks       | MPH+Clonidine MPH only Clonidine only | Placebo                  | ADHD symptoms improved without aggravation of tics |
| Gadow et al. [23]        | 2007  | 71                  | 6–12          | 15 years       | MPH 0.1, 0.3, 0.5 mg/kg | Placebo                  | ADHD symptoms improved without aggravation of tics |

ADHD, attention deficit hyperactivity disorder; AMP, amphetamine; MPH, methylphenidate
and placebo groups. The clonidine only, methylphenidate only, and clonidine+methylphenidate groups showed decreased Conners Abbreviated Symptom Questionnaire scores compared to the placebo group. In particular, clonidine was effective in improving hyperactivity and impulsivity, while methylphenidate was effective in improving inattention. In contrast, 20%, 26%, and 22% of the methylphenidate, clonidine, and placebo groups, respectively, showed worsening of tics with no differences between the groups. In addition, in objective evaluation using a measurement tool, the YGTSS score decreased in the order of clonidine+methylphenidate, clonidine only, and methylphenidate only groups compared to the placebo group.

Therefore, if tics develop or worsen after the administration of stimulants in patients with ADHD, the following confounding variables can be considered. First, tics have a natural course of wax and wane in terms of frequency and severity [18]. In most patients, tics develop or worsen a few days to one year after the administration of stimulants [26,27]. Clinicians must follow-up with the patients for more than three months to ensure that such a phenomenon is not a natural course of tic [28]. In other words, clinicians must check whether such temporal relationships of tics develop and worsen immediately after administration of stimulants or if disappearing and relieving immediately upon discontinuation of the drug is repeated. Second, the onset of tics often overlaps with the time when ADHD symptoms are discovered and medication is initiated. As previously described, motor tics are commonly observed between the age of three and eight, and ADHD develops a few years earlier. Among them, the prevalence of provisional tics is up to 20% [29]. Many patients often neglect or are unaware of provisional tics and may misunderstand that tics have developed due to medication for ADHD treatment. Most patients who developed tics after a certain amount of time from the first use of stimulations to treat ADHD were younger than those who did not [30,31]. This supports the hypothesis that stimulants may play a role in the early triggers of tic development rather than in causing tics [26]. Third, the initial symptoms of tics are similar to those of hyperactivity observed in ADHD. As tics are naturally aggravated following the administration of stimulants, it may be misunderstood that stimulants may have caused tics [19]. Lastly, fatigue and stress worsen tics, and most children with ADHD are treated for the first time using stimulants as they enter elementary school, which may be stressful. Unlike before, children are exposed to serious stress as they study and build new relationships with peers in a structured school environment [32].

ADHD with tic disorder shows poor cognitive performance, such as reduced executive functions, learning ability, and sustained attention, and difficulties in getting along with their peers [33-36]. These cognitive and behavioral problems are related more to ADHD than tic symptoms. Moreover, externalizing problems such as aggressive behaviors, tantrums, oppositional behaviors, and conduct behaviors are closely related to ADHD [37-39]. To recover from such extensive functional impairment observed in children with ADHD accompanied by tic disorders, symptoms of ADHD must be treated first. Stimulants are effective in improving the symptoms of ADHD regardless of the tic disorder and are an important treatment method [40]. Therefore, although tics may develop or worsen after the use of stimulants, clinicians must observe patients without discontinuing or reducing the stimulant dose. However, if tics do not improve over time or cause severe functional impairment, stimulants may be reduced or discontinued and re-administered once they are relieved [41]. In this case, clonidine can be added to or replace the stimulants, and these options are effective for both ADHD and tics [24,42]. Non-stimulants such as atomoxetine and D2-blockers such as aripiprazole may also be alternatives [40].

Stimulants induce dopamine (DA) secretion. In contrast, anti-tic medications act as antagonists of dopaminergic function. Therefore, it is logical to suspect that stimulants may cause tics. In addition, individual cases in which the onset or aggravation of tics is induced by medication may be observed. In fact, in 5%–7% of patients, tics develop or worsen after the use of stimulants [41]. However, this rate is similar to that induced by placebo administration, and a greater number of patients did not develop or show worsening of tics after the use of medication. In other words, various confounding variables, as well as neural circuits related to the onset of tics, complex relationships between neurotransmitters, and individual factors such as genetic vulnerability must be comprehensively considered. In conclusion, as the development or worsening of tics after the use of stimulants is likely to be coincidental and the wide range of functional impairment caused by ADHD and comorbidities is greater than that caused by tic symptoms, clinicians must prioritize using stimulants to treat ADHD.

**STEREOTYPIES AND OTHER MOVEMENT DISORDERS**

Stimulants induce stereotypies, chorea, and dyskinesia, in addition to tics [43]. Stereotypies are rhythmic and involuntary movements that are repeated without purpose. Although there are many animal studies on amphetamine-induced grooming, facial grimacing, gnawing, and lip licking [44], there are only a few studies on humans, most of which are mainly related to addiction rather than treatment [45].

Chorea is an irregular and involuntary movement character-
Stimulant Induced Movement Disorders in ADHD

PD is the second most common neurodegenerative disorder in the elderly, after Alzheimer’s dementia. The incidence of PD increases rapidly every year after the age of 60 years, and its prevalence is slightly higher in men than in women [52]. Various studies have sought to determine the cause of PD, and various genetic and environmental factors are involved in its pathogenesis. PD is diagnosed based on a combination of abnormal motor symptoms, including resting tremor, rigidity, bradykinesia, impaired posture, and balance. Although motor symptoms are the main symptoms of PD, other non-motor signs and symptoms are observed before the onset or symptoms of PD [53]. These include sleep problems, such as rapid eye movement sleep behavior disorder, olfactory dysfunction, such as hyposmia, and other symptoms of constipation, cognitive impairment, and depression.

PD is caused by the degeneration of DA neurons in the substantia nigra (SN) and the abnormal misfolding and aggregation of mutant α-synuclein [54,55]. DA neurons in the SN are more sensitive to mutant α-synuclein than those in other parts of the brain [54].

PD and ADHD are closely related. Both diseases are related to functional changes in DA neurons in the midbrain [56]. In transcranial cranial sonography (TCS), SN hyperechogenicity is observed in both patients with PD and children with ADHD [57,58]. In addition, both PD and ADHD are associated with pathological abnormalities in the brain regions (for example, dorsal striatum and nucleus accumbens) projected by DA neurons in the midbrain. In PD, abnormal biomarker findings that indicate DA function in the dorsal striatum are often observed. Among these biomarkers, abnormal findings in dopamine transporter (DAT) proteins are frequently observed in patients with ADHD [56]. Stimulants used for the treatment of ADHD block the binding of DAT and DA in neuron synapses, thereby increasing the concentration of DA in the synapses for therapeutic effects. The use of stimulants changes DAT expression levels in synapses. In a study using single photon emission tomography and positron emission tomography (PET), DAT level in the striatum was higher in patients with ADHD who underwent stimulant treatment for a longer period than in drug-naïve patients with ADHD [59]. Moreover, neuropsychological tests have shown similar cognitive deficits between patients with ADHD and those with PD [56]. Both ADHD and PD are often accompanied by psychiatric disorders such as depression and anxiety disorder, and stimulants help to improve cognitive deficits in PD. These findings indirectly suggest an association between ADHD and PD [56]. Cognitive disturbances and psychiatric disorders are common comorbidities in PD. This suggests that DA nerve

ized by unpredictable ‘dancing’ of muscle contractions. The first case of chorea caused by the use of stimulants was reported in an 8-year-old boy whose upper extremity chorea worsened after the administration of 5 mg amphetamine for hyperactivity [46]. Symptoms improved immediately after discontinuing the medications and challenges using the same dose of amphetamine-aggravated chorea. Melvin and Heiraty [47] reported a case of a 10-year-old girl who developed writhing, irregular hand movement, and twisting ‘dance-like’ gait after increasing methylphenidate OROS dose from 36 mg to 54 mg for treatment of ADHD. Abnormal movements were relieved within 24 h of discontinuation of medication and administration of lorazepam. The movements were no longer observed after three weeks. Recently, a case of a 6-year-old boy with Sydenham chorea as an sequela of acute rheumatic fever was reported [48]. The child was administered 18 mg of methylphenidate OROS for the treatment of ADHD, and in three days, the choreiform movement was aggravated in the extremities. Abnormal movement severity, evaluated using the Chorea intensity scale, increased from 12 to 27 points, and then decreased to 11 points after 2 weeks of discontinuing methylphenidate OROS. Subsequently, 10 mg of atomoxetine was administered, the dose was increased to 25 mg, and chorea did not aggravate. As such, stimulants at clinical therapeutic doses may cause the worsening of chorea. In these cases, medications may be discontinued or changed, and D2-blocker, benzodiazepine, and diphenhydramine may be used instead [49]. However, there is no clear consensus on the treatment of stimulant-induced chorea.

Although there are many case reports of dyskinesia after the administration of stimulants in therapeutic settings, only a few studies have compared stimulants to controls. In one case-control study, the ADHD group treated with methylphenidate had a higher abnormal involuntary movement scale (AIMS) score at baseline than the control group [50]. However, a single dose of methylphenidate did not alter the AIMS score. Keresztény et al. [51] compared three groups: drug-naïve ADHD, stimulant treatment, and healthy controls. The ADHD group treated with methylphenidate had a higher AIMS score than the other two groups, and dyskinesia was mainly observed in the orofacial area and upper extremities. In contrast, the AIMS scores were not significantly different between the drug-naïve ADHD and healthy control groups. This finding suggests that dyskinesia is not an inherent characteristic of ADHD. Recently, dyskinesia has been added to the drug labels and instructions as a side effect of methylphenidate. Clinicians must carefully examine dyskinesia when treating patients with ADHD with stimulants.
system disorder in PD is not limited to the nigrostriatal DA system and is related to dopaminergic pathways and other neurotransmitter systems [60]. In fact, methamphetamine (METH) causes sustained damage to the DA nerve terminal as well as the serotonin nerve terminal [61].

Animal studies on amphetamines and neurotoxicity studies on abusers of illegal stimulants suggest that stimulants are one of the many neurotoxins that cause PD [56]. However, in most animal studies, stimulants were used at significantly higher doses than those used for the clinical treatment of patients with ADHD. There are only a few studies on the neurotoxicity of stimulants in humans, and most of these limited number of studies have been conducted on METH abusers. In post-mortem studies, METH abusers had reduced striatal DA, TH, and DAT levels; however, the findings were different from those observed in patients with PD [62,63]. Possible explanations for such differences include the mean age of METH abusers to be 30 years in the post-mortem studies, which is an early age for symptoms of PD [62,64]. In a PET study of chronic METH abusers, DAT was reduced. Although participants discontinued METH (abstinent state), decreased striatal DA and memory deficits persisted [65,66]. In another study, TCS was used to determine differences in SN echogenic signals between chronic amphetamine abusers and controls. In that study, the amphetamine abuser group had higher echogenicity than the control group [67,68]. In another study using TCS to evaluate differences in echogenic signals and PD symptoms between amphetamine abusers and controls (ecstasy, cannabis, and non-drug users), the amphetamine group showed hyperechogenicity in the SN [69]. Patient group that used amphetamines (amphetamine, METH, d-amphetamine) more than twice a week for more than three months or weekly for more than a year had more occurrences of PD than the control group (patient spouses or caregivers). PD develops after an average of 27 years of exposure to amphetamines [70]. Additionally, in another survey conducted by the same group of investigators using the same method, patients with PD with a history of long-term exposure to amphetamines developed the disease approximately three years earlier on average than those without such history. However, there were no differences in the characteristics of the symptoms and MRI findings [71].

Methylphenidate has relatively low neurotoxicity compared with amphetamines [72,73]. Some animal studies have reported that methylphenidate can induce neurotoxicity and continuous exposure to methylphenidate in early life can lead to persistent problems in the development of the DA nervous system [74,75]. However, in a study using brain MRI to examine the differences between methylphenidate and placebo groups of adult ADHD patients, there was no detectable cerebral volume loss in the methylphenidate group at three and 12 months of administration. Instead, there was an increasing trend toward bilateral cerebellar gray matter [76].

There is insufficient evidence to explain why methylphenidate is relatively safe compared to amphetamines. As previously described, aggregation and misfolding of intracellular α-synuclein in neurons often leads to neurodegenerative diseases, such as dementia with Lewy bodies and PD. Amphetamines have a higher affinity for the N-terminus than for the C-terminus of α-synuclein, which induces misfolding of α-synuclein. In contrast, methylphenidate binds to both N- and C-termini to form a loop conformation, which does not cause α-synuclein misfolding [54,77].

In addition, methylphenidate has been used to decrease cognitive, affective, and motor deficits in PD, even in advanced cases [78-86]. Methylphenidate is known to improve motor function in PD [78,79]. Chronic administration of high doses of methylphenidate improved gait and reduced excessive daytime sleepiness in patients with advanced PD [80]. Methylphenidate has also shown positive effects on anhedonia and vigor in patients with PD [82]. After more than a year of levodopa treatment, acute methylphenidate increased positive affect (reward responsiveness) [83] and improved apathy in patients with advanced PD [84]. Auriel et al. [85] reported improved attention in patients with PD after the administration of a single dose of methylphenidate. Fatigue is also a common non-motor symptom in PD; methylphenidate improved fatigue in a randomized, double-blind, placebo-controlled trial [86]. Although these results are promising, further research is required.

Some findings have indicated that stimulants may induce PD [64,87]. Baumeister [64] summarized previous epidemiological study findings on the trend of PD and suggested that stimulants might cause PD. In a recent retrospective cohort study, the association between ADHD and PD was investigated in people born between 1950 and 1992 in Utah, USA [87]. The prevalence of basal ganglia and cerebellum (BG&C)-related diseases (such as PD, secondary PD, essential tremor, and other degenerative diseases of the basal ganglia) was 2.4 times higher in those diagnosed with ADHD than in the control group. Additionally, the prevalence of BG&C-related diseases was six times higher in those who received stimulants and eight times higher in those who received only methylphenidate than in those in the control group. The researchers argued that the use of stimulants in ADHD patients could increase the incidence of PD, while suggesting that caution is needed in interpreting the results. In other words, the use of stimulants such as methylphenidate in patients with ADHD does not directly increase the incidence of PD; however, patients with ADHD who use stimulants may have more severe ADHD symptoms than drug-naïve patients, which may be re-
related to PD. Furthermore, researchers pointed out that factors that may increase the incidence of PD may not have been controlled. As the study not only investigated the incidence of PD but also included BG&C related diseases (for example, essential tremor), stimulants may not directly increase the incidence of PD [56,87]. In a genetic linkage study on a possible genetic link between ADHD and PD, none of the nine candidate genes showed any association between ADHD and PD, suggesting that the genetic link between the two diseases is low [88].

CONCLUSION

Many studies have investigated whether the use of stimulants in patients with ADHD causes or worsens abnormal movements. Tic disorders are the most commonly studied type of disease. Contrary to the initial belief, recent studies have reported that stimulants may be a factor that influences emotion rather than causing tic symptoms. Studies on abnormal motor symptoms other than tics are mostly case reports, and further evidence is required. Stimulants have been used to treat ADHD for the last several decades, and it is controversial whether these medications act as neurotoxins which cause PD. As the life expectancy of the human race has increased, the incidence of degenerative diseases, such as PD, has rapidly increased. Studies on whether stimulants can affect the onset of PD have mainly been conducted on animals or on illegal drug abusers using METH. Although many studies have reported that among the stimulants used to treat ADHD, methylphenidate is relatively safe compared to amphetamines, recent epidemiological studies have shown that methylphenidate may also increase the incidence of BG&C-related diseases such as PD. However, there is still a lack of evidence to support that the use of stimulants in patients with ADHD may be a direct cause of PD, and related studies are in the early stages. As stimulants are one of the most commonly used medications in children and adolescents, close observations and studies are necessary in the future to assess their effects on the development of movement disorders.

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: all authors. Data curation: Seok-Hyun Nam, Tae Won Park. Formal analysis: Seok-Hyun Nam, Tae Won Park. Investigation: Seok-Hyun Nam, Tae Won Park. Methodology: Myung Ho Lim, Tae Won Park. Project administration: all authors. Resources: Seok-Hyun Nam, Tae Won Park. Software: Seok-Hyun Nam, Myung Ho Lim. Supervision: Myung Ho Lim, Tae Won Park. Validation: all authors. Writing—original draft: Seok-Hyun Nam, Tae Won Park. Writing—review & editing: all authors.

ORCID iDs

Seok-Hyun Nam https://orcid.org/0000-0003-3972-1553
Myung Ho Lim https://orcid.org/0000-0001-5370-4376
Tae Won Park https://orcid.org/0000-0001-5980-0756

Funding Statement

None

REFERENCES

1) Brown RT, Freeman WS, Perrin JM, Stein MT, Amster RN, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001;107: E43.
2) Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res 2010;177:299-304.
3) Weiss G, Hechtman I, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985;24: 211-220.
4) Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011;127:462-470.
5) The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086.
6) Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727-738.
7) Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 2009;34:678-694.
8) Baumeister AA, Henderson K, Pow JL, Advokat C. The early history of the neuroscience of attention-deficit/hyperactivity disorder. J Hist Neurosci 2012;21:263-279.
9) Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17-25.
10) Scheffer RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood) 2007;26:450-457.
11) Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nicholas SD, et al. Trends in use of prescription stimulants in the United States and territories, 2006 to 2016. PLoS One 2018;13:e0206100.
12) Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol 2015;6:75.
13) Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998;102:14-19.
14) Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatri Neurol 2012;47:77-90.
15) Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 2000;42:436-447.
16) Swanson J, Lerner M, March J, Gresham FM. Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study. Pediatr Clin North Am 1999;46:993-1009.
17) Steinhausen HC, Novik TS, Baldursson G, Curatolo P, Lorenzo MJ, Rodrigues Pereira R, et al. Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006;15:125-139.

18) Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-1586.

19) Golden GS. Gilles de la Tourette's syndrome following methylphenidate administration. Dev Med Child Neurol 1974;16:76-78.

20) Lowe TL, Cohen DJ, Detlor J, Kremenizer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. JAMA 1982;247:1168-1169.

21) Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1997;36:589-596.

22) Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, et al. Controlled stimulant treatment of ADHD and comorbid Tourette syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997;36:589-596.

23) Gadow KD, Sverd J, Nolan EE, Sprafkin J, Schneider J. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry 2007;46:840-848.

24) Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58:527-536.

25) Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999;103:730-737.

26) Shapiro AK, Shapiro E. Do stimulants provoke, cause, or exacerbate tics and Tourette syndrome? Compr Psychiatry 1981;22:265-273.

27) Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette’s syndrome: effects of stimulant drugs. Neurology 1985;35:1346-1348.

28) Rizzo R, Gulsano M, Cali PV, Curatolo P. Tourette syndrome and comorbid ADHD: current pharmacological treatment options. Eur J Pediatr Neurol 2013;17:421-428.

29) Scellill S, Specht M, Page C. The prevalence of tic disorders and clinical characteristics in children. J Obsessive Compuls Relat Disord 2014;3:394-400.

30) Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 2001;42:228-233.

31) Spencer T, Biederman M, Coffey B, Geller D, Wilsen T, Faraone S. The 4-year course of tic disorders in boys with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 1999;56:842-847.

32) Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosex Res 2009;6:497-501.

33) Harris EL, Schuerholz LJ, Singer HS, Reader MJ, Brown JE, Cox C, et al. Executive function in children with Tourette syndrome and/or attention deficit hyperactivity disorder. J Int Neuropsychol Soc 1995;1:511-516.

34) Schuerholz LJ, Baumgardner TL, Singer HS, Reiss AI, Denckla MB. Neuropsychological status of children with Tourette's syndrome with and without attention deficit hyperactivity disorder. Neurology 1996;46:958-965.

35) Sherman EM, Shepard L, Joschko M, Freeman RD. Sustained attention and impulsivity in children with Tourette syndrome: comorbidity and confounds. J Clin Exp Neuropsychol 1998;20:644-657.

36) Stokes A, Bawden HN, Camfield PR, Backman JE, Dooley JM. Peer problems in Tourette's disorder. Pediatrics 1991;87:936-942.

37) Pierre CB, Nolan EE, Gadow KD, Sverd J, Sprafkin J. Comparison of internalizing and externalizing symptoms in children with attention-deficit hyperactivity disorder with and without comorbid tic disorder. J Dev Behav Pediatr 1999;20:170-176.

38) Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorder: a pilot study. J Clin Psychopharmacol 1998;18:576-580.

39) Sukhodolsky DG, Scabill L, Zhang H, Peterson BS, King RA, Lombroso PI, et al. Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry 2003;42:98-105.

40) Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009;48:884-893.

41) Cohen SC, Mulqueen JM, Ferraccioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2015;54:728-736.

42) Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 1999;38:614-619; discussion 619-622.

43) Lopez W, Jeste DV. Movement disorders and substance abuse. Psychiatr Serv 1997;48:634-636.

44) Randrup A, Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia 1967;11:300-310.

45) Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972;75:203-212.

46) Mattson RH, Calverley JR. Dextroamphetamine-sulfate-induced dyskinesias. JAMA 1968;204:400-402.

47) Melvin KE, Heiraty P. Acute chorea in a child after starting methylphenidate: a case report. Cureus 2013;5:e90.

48) Ekinci O, Yaşöz C, İpek Baş SA, Ekinci N, İpek Doğan Ö. Methylphenidate-induced exacerbation of chorea in a child resolved with switching to atomoxetine. Clin Psychopharmacol Neurosci 2020;18:327-330.

49) Gilbert DL. Acute and chronic chorea in childhood. Semin Pediatr Neurol 2009;16:71-76.

50) Balázs J, Dallos G, Keresztény A, Czobor P, Gádoros J. Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21:133-138.

51) Keresztény Á, Ferenczi-Dallos G, Velő S, Gádoros J, Balázs J. Dyskinesia in treatment-naive and stimulant-treated children with ADHD. J Atten Disord 2020;24:981-989.

52) Van Den Eeden SK, Tanner CM, Bernstein AL, Fuss RD, Lempeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.

53) Goldman JG, Postuma R. Promotor and nonmotor features of Parkinson's disease. Curr Opin Neurol 2014;27:434-441.

54) Subramaniam M, Althof D, Gispeert S, Schwenk J, Auburger G, Kulik A, et al. Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. J Neurosci 2014;34:13568-13599.

55) Beyer K, Domingo-Sábat M, Ariza A. Molecular pathology of Lewy body diseases. Int J Mol Sci 2009;10:724-745.

56) Baumeister AA. Is attention-deficit/hyperactivity disorder a risk syndrome for Parkinson's disease? Harv Rev Psychiatry 2021;29:142-158.

57) Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, et al. Enlarged hyperthecogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013;28:216-219.

58) Krauel K, Feldhaus HC, Simon A, Rehe C, Glaser M, Flechtnet
Stimulant Induced Movement Disorders in ADHD

HH, et al. Increased echogenicity of the substantia nigra in children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry 2010;68:352-358.

59 Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopaminergic transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169:264-272.

60 Caminiti SP, Pretoso L, Barocini D, Garibotto V, Moreno RM, Giannoli L, et al. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. Neuroimage Clin 2017;14:734-740.

61 Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci 2014;97:37-44.

62 Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in humans, chronic methamphetamine users. Nat Med 1996;2:699-703.

63 Moszczyńska A, Fitzmaurice P, Ang I, Kalasinsky KS, Schmuck GA, Peretti FJ, et al. Why is parkinsonism not a feature of human methamphetamine users? Brain 2004;127:363-370.

64 Baumeister AA. Could clinical use of stimulant medications increase risk for Parkinson's disease or other neurological sequelae? A review of the evidence. J Pharmacol Clin Res 2017;3:55518.

65 Volkow ND, Chang I, Wang GJ, Fowler JS, Leónido-Yee M, Fraseschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-382.

66 McCann UD, Kowabara H, Kumar A, Palermo M, Abbe R, Brescia J, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008;62:91-100.

67 Rumpf JJ, Albers J, Fricke C, Mueller W, Classen J. Structural abnormality of substantia nigra induced by methamphetamine abuse. Mov Disord 2017;32:1784-1788.

68 Todd G, Pearson-Dennett V, Wilcox RA, Chau MT, Thoirs K, Thewlis D, et al. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism Relat Disord 2016;25:27-32.

69 Todd G, Voines C, Flavel SC, Delia Vedova CB, Spyropoulos P, Chatterton B, et al. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One 2013;8:e56438.

70 Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 2006;27:1003-1006.

71 Christine CW, Garwood ER, Schrof LE, Austin DE, McCulloch CE. Parkinsonism in patients with a history of amphetamine exposure. Mov Disord 2010;25:228-231.

72 Ludolph AG, Schau U, Storch A, Liebua S, Fegert JM, Boeckers TM. Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J Neural Transm (Vienna) 2006;113:1927-1934.

73 Zaczek R, Battaglia G, Contrera JF, Culp S, De Souza EB. Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol Appl Pharmacol 1989;100:227-233.

74 Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeayre RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 2012;7:e33693.

75 Moll GH, Hause S, Rüther E, Rothenberger A, Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001;11:15-24.

76 Tebartz van Elst I, Maier S, Klöppel S, Graf E, Killius C, Rump M, et al. The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. J Psychiatry Neurosci 2016;41:422-430.

77 Kakish J, Lee D, Lee JS. Drugs that bind to α-synuclein: neuroprotective or neurotoxic? ACS Chem Neurosci 2015;6:1930-1940.

78 Camicioli R, Lea E, Nitt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol 2001;24:208-213.

79 Pollak L, Dobromelsky Y, Prohorov T, Bahunker S, Rabey JM. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl 2007;72:145-148.

80 Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:470-475.

81 Devos D, Moreau C, Delval A, Dujardin K, Defebvre L, Bordet R. Methylphenidate: a treatment for Parkinson's disease? CNS Drugs 2013;27:1-14.

82 Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci 2012;320:121-126.

83 Evans AH, Lawrence AD, Lees AJ. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:267-272.

84 Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petty G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-596.

85 Aurie E, Hausdorff JM, Giladi N. Methylphenidate for the treatment of Parkinson disease and other neurological disorders. Clin Neuropharmacol 2012;35:75-81.

86 Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076.

87 Curtin K, Fleckenstein AE, Keeshin BR, Yurgelun-Todd DA, Renshaw PF, Smith KR, et al. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology 2018;43:2548-2555.

88 Geissler JM, Romanos M, Gerlach M, Berg D, Schulte C. No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs. Atten Defic Hyperact Disord 2017;9:121-127.